Jun 19, 2020
Roche receives FDA approval for cobas EZH2 Mutation Test as a companion diagnostic for patients with follicular lymphoma
Apr 22, 2020
Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Nov 04, 2019
Ascentage Pharma and Henlius Form a Combination Therapy Strategic Collaboration
Sep 20, 2019
Innovent Provides Update on Two Studies of IBI301 (Rituximab Biosimilar) in the Treatment of CD20-positive Lymphoma at Annual Meeting of CSCO
Aug 22, 2019
Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)
Aug 06, 2019
ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial
Jul 16, 2019
Ublituximab Drug Overview 2019: An Anti-CD20 Monoclonal Antibody, Currently in Late-Stage Trials Across a Range of Hematological and Neurological Indications
Jul 15, 2019
Umbralisib (TG Therapeutics/Rhizen) Drug Overview & Product Profiles 2017-2018 & 2019-2026
Jul 12, 2019
Rituxan (rituximab; Biogen/Roche/Chugai/Zenyaku Kogyo) Drug Overview & Product Profiles 2016-2026
Jul 12, 2019
Global Treanda (bendamustine; Teva/Mundipharma/Eisai Drug Overview & Product Profiles 2017-2026
Jul 08, 2019
Zanubrutinib (BeiGene) Drug Overview and Product Profiles 2017-2026
Jul 08, 2019
Copiktra (Duvelisib; Verastem/Yakult Honsha) Drug Overview & Product Profiles 2017-2026
Jun 19, 2019
Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma
Jun 14, 2019
Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures
Jun 03, 2019
MEI Pharma Presents Updated Clinical Data from the ME-401 Monotherapy and in Combination with Rituximab Phase 1b study in Patients with Follicular Lymphoma at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
May 21, 2019
Nordic Nanovector: Archer-1 Phase 1b Betalutin®/Rituximab Combination Trial Advances to Next Cohort
Feb 19, 2019
CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Confirmatory Clinical Trial For ZEVALIN®
Jan 30, 2019
BioInvent Receives FDA Orphan Designation for BI-1206 for Mantle Cell Lymphoma
Dec 27, 2018
Xynomic Pharma Will Present at ASCO-GU Cancers Symposium, Files 3 INDs for Potentially Pivotal Cancer Trials in China, and Expands R&D Operations
Dec 02, 2018
MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Hematology Annual Meeting